Liquidia (Liquidia) 6-1 Month Momentum % : 138.08% (As of May. 03, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Liquidia 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-03), Liquidia's 6-1 Month Momentum % is 138.08%.

The industry rank for Liquidia's 6-1 Month Momentum % or its related term are showing as below:

LQDA's 6-1 Month Momentum % is ranked better than
90.46% of 1520 companies
in the Biotechnology industry
Industry Median: 3.75 vs LQDA: 138.08

Competitive Comparison of Liquidia's 6-1 Month Momentum %

For the Biotechnology subindustry, Liquidia's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Liquidia's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liquidia's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Liquidia's 6-1 Month Momentum % falls into.

Liquidia (NAS:LQDA) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liquidia (NAS:LQDA) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Liquidia 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Liquidia's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Liquidia (Liquidia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (NAS:LQDA) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

LT4:Germany LT4:Germany

Address

419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560

Website

https://www.liquidia.com

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension.

Executives

Rajeev Saggar	officer: Chief Medical Officer	419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Jason Adair	officer: V.P. Crp Dvlpmnt and Strtgy	C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Paul B Manning	director, 10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Roger Jeffs	director
Caligan Partners Lp	director, 10 percent owner, other: See Remarks	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Robert A Lippe	officer: Chief Operations Officer	C/O ALEXZA PHARMACEUTICALS, INC., 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Scott Moomaw	officer: SVP, Commercial	P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Michael Kaseta	officer: Chief Financial Officer	7100 WEST CREDIT AVENUE, SUITE 101, MISSISSAUGA A6 L5N OE4
Russell Schundler	officer: General Counsel	P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Arthur S Kirsch	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
David Edward Johnson	10 percent owner	590 MADISON AVENUE, NEW YORK NY 10022
Katherine Rielly-gauvin	director	419 DAVIS DRIVE, MORRISVILLE NC 27560
Raman Singh	director	C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Joanna Horobin	director	215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142
Stephen M Bloch	director	285 RIVERSIDE AVENUE, SUITE 250, WESTPORT CT 06880